Candel Therapeutics Stock Revenue
| CADL Stock | USD 4.71 0.00 0.00% |
Candel Therapeutics fundamentals help investors to digest information that contributes to Candel Therapeutics' financial success or failures. It also enables traders to predict the movement of Candel Stock. The fundamental analysis module provides a way to measure Candel Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Candel Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 31 K | 29.4 K |
Candel | Revenue |
Candel Therapeutics Company Revenue Analysis
Candel Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Candel Therapeutics Revenue | 31 K |
Most of Candel Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Candel Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Candel
Projected quarterly revenue analysis of Candel Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Candel Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Candel Therapeutics' stock price.
Candel Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Candel Therapeutics is extremely important. It helps to project a fair market value of Candel Stock properly, considering its historical fundamentals such as Revenue. Since Candel Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Candel Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Candel Therapeutics' interrelated accounts and indicators.
| 0.65 | -0.42 | -0.78 | 0.54 | 0.96 | ||
| 0.65 | -0.94 | -0.34 | 0.93 | 0.8 | ||
| -0.42 | -0.94 | 0.0 | -0.91 | -0.58 | ||
| -0.78 | -0.34 | 0.0 | -0.22 | -0.73 | ||
| 0.54 | 0.93 | -0.91 | -0.22 | 0.7 | ||
| 0.96 | 0.8 | -0.58 | -0.73 | 0.7 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Candel Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Candel Therapeutics reported 31 K of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Candel Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Candel Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Candel Therapeutics could also be used in its relative valuation, which is a method of valuing Candel Therapeutics by comparing valuation metrics of similar companies.Candel Therapeutics is currently under evaluation in revenue category among its peers.
Candel Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Candel Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Candel Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Candel Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Candel Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Candel Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Candel Therapeutics' value.| Shares | Bank Of New York Mellon Corp | 2024-06-30 | 54.4 K | Bank Of America Corp | 2024-06-30 | 54.4 K | Charles Schwab Investment Management Inc | 2024-09-30 | 46.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 38.9 K | Advisor Group Holdings, Inc. | 2024-06-30 | 25.8 K | Rhumbline Advisers | 2024-06-30 | 23 K | Virtu Financial Llc | 2024-06-30 | 22.6 K | Vontobel Holding Ltd. | 2024-06-30 | 22 K | Jpmorgan Chase & Co | 2024-06-30 | 19.4 K | Northpond Ventures, Llc | 2024-09-30 | 1.9 M | Vanguard Group Inc | 2024-09-30 | 946.3 K |
Candel Fundamentals
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 160.22 M | ||||
| Shares Outstanding | 32.48 M | ||||
| Shares Owned By Insiders | 30.39 % | ||||
| Shares Owned By Institutions | 22.53 % | ||||
| Number Of Shares Shorted | 2.1 M | ||||
| Price To Book | 30.41 X | ||||
| Price To Sales | 436.42 X | ||||
| Revenue | 31 K | ||||
| Gross Profit | (20.66 M) | ||||
| EBITDA | (37.43 M) | ||||
| Net Income | (37.94 M) | ||||
| Cash And Equivalents | 86.78 M | ||||
| Cash Per Share | 3.00 X | ||||
| Total Debt | 22.76 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 14.86 X | ||||
| Book Value Per Share | 0.44 X | ||||
| Cash Flow From Operations | (34.24 M) | ||||
| Short Ratio | 7.72 X | ||||
| Earnings Per Share | (1.73) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 42 | ||||
| Beta | -0.87 | ||||
| Market Capitalization | 134.29 M | ||||
| Total Asset | 41.2 M | ||||
| Retained Earnings | (137.03 M) | ||||
| Working Capital | 22.61 M | ||||
| Net Asset | 41.2 M |
About Candel Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Candel Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Candel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Candel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Candel Therapeutics Piotroski F Score and Candel Therapeutics Altman Z Score analysis. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.